chevron-down Created with Sketch Beta.
June 11, 2021

FDA Approves Drug Intended to Slow Cognitive Decline But Debate About Its Effectiveness Persists

On June 7, the FDA approved Aducanumab, an Alzheimer’s treatment intended to slow cognitive decline. Aducanumab is the first drug designed to alter the course of the disease by slowing the deterioration of brain function, not just ease symptoms. The FDA’s approval is subject to the drug-maker conducting a post-approval study confirming the drug actually slows cognitive decline.